Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

NCT00684177 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

508

Enrollment

INDUSTRY

Sponsor class

Conditions

Skin Infections, Bacterial

Interventions

DRUG: Retapamulin Ointment, 1%
DRUG: Placebo ointment

Sponsor

GlaxoSmithKline